Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › trastuzumab

trastuzumab

14 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of trastuzumab

197 trials tracked of trastuzumab: 57 in phase 3 or 4 and 33 with published results. The most-cited published study has 2781 citations.

197Trials tracked
57Phase 3 & 4
0Recruiting
33With published results
Phase distribution
Phase 4 4 Phase 3 53 Phase 2 124 Phase 1 11 Other / NA 5
  1. Phase 3 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed · 2,781 cited
  2. Phase 3 A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE) Completed · 2,627 cited
  3. Phase 3 Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer Completed · 1,513 cited
  4. Phase 3 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Completed · 693 cited
  5. Phase 3 A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 534 cited
  6. Phase 3 Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer Completed · 492 cited
Show 44 more trials
  1. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric Cancer Completed · 480 cited
  2. Phase 3 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Completed · 421 cited
  3. Phase 3 DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] Completed · 352 cited
  4. Phase 3 Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer Completed · 351 cited
  5. Phase 3 Everolimus in Combination With Trastuzumab and Paclitaxel in the Treatment of HER2 Positive Locally Advanced or Metastatic Breast Cancer Completed · 307 cited
  6. Phase 3 Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel Completed · 193 cited
  7. Phase 3 A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer Completed · 166 cited
  8. Phase 3 Study of Efficacy and Safety of Myl1401O + Taxane vs Herceptin©+ Taxane for 1st Line, Met. Br. Ca. Completed · 145 cited
  9. Phase 3 Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer Completed · 123 cited
  10. Phase 3 A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer Completed · 114 cited
  11. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 114 cited
  12. Phase 3 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Completed · 104 cited
  13. Phase 3 A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer Completed · 100 cited
  14. Phase 3 Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Completed · 99 cited
  15. Phase 3 Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast Cancer Completed · 98 cited
  16. Phase 3 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer Completed · 64 cited
  17. Phase 3 A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02) Completed · 60 cited
  18. Phase 3 A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Completed · 49 cited
  19. Phase 3 A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 46 cited
  20. Phase 3 A Study of Subcutaneous At Home Administration of Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2-positive (HER2+) Early Breast Cancer (eBC) Completed · 43 cited
  21. Phase 3 Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer Completed · 37 cited
  22. Phase 3 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Completed · 31 cited
  23. Phase 3 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Completed · 28 cited
  24. Phase 3 A Continuation Study of Herceptin (Trastuzumab) in Participants With Metastatic or Locally Advanced Cancer Completed · 26 cited
  25. Phase 3 A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer Completed · 20 cited
  26. Phase 3 A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients Completed · 17 cited
  27. Phase 3 A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 12 cited
  28. Phase 4 A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment Completed
  29. Phase 4 Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer Completed
  30. Phase 4 Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen Completed
  31. Phase 4 XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer Completed
  32. Phase 3 A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) Completed
  33. Phase 3 Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer Completed
  34. Phase 3 Extension Study to Provide Adjuvant Treatment Following Neoadjuvant Treatment and Surgical Resection in Protocol TX05-03 Completed
  35. Phase 3 Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Completed
  36. Phase 3 Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer Completed
  37. Phase 3 Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer Completed
  38. Phase 3 Demonstrate Efficacy and Safety of Metastatic Breast Cancer Completed
  39. Phase 3 Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer Completed
  40. Phase 3 A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer Completed
  41. Phase 3 Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery Completed
  42. Phase 3 THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer. Completed
  43. Phase 3 Combination Chemotherapy and Paclitaxel Plus Trastuzumab in Treating Women With Palpable Breast Cancer That Can Be Removed by Surgery Completed
  44. Phase 3 Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer Completed

Showing the 50 most-cited and recently-updated of 197 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Phase II trial protocol examines HER2-PET imaging to predict trastuzumab deruxtecan response in HER2-low metastatic breast cancer
Oncology Cohort
Phase II trial protocol examines HER2-PET imaging to predict trastuzumab deruxtecan response in HER2-low metastatic breast cancer A Full-Body Scan May Soon Decide Who Benefits From This Breast Cancer Drug
A multicenter, prospective, open-label phase II trial protocol will enroll 70 patients with HER2-low metastatic breast cancer.
A whole-body imaging scan may one day replace a single biopsy for matching patients to targeted breast cancer therapy.
Frontiers Apr 13, 2026
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients
OB/GYN & Women's Health Phase II
Phase II trial of cyclophosphamide, paclitaxel, trastuzumab in stage I-II HER2+ breast cancer completes with 20 patients Can a shorter, more intense chemo regimen help prevent early-stage HER2-positive breast cancer from returning?
A phase II trial evaluated a dose-dense regimen of cyclophosphamide, paclitaxel, and trastuzumab after surgery in 20 patients with stage I-I…
For women with early-stage HER2-positive breast cancer, a key question is whether a shorter, more intense chemotherapy schedule after surger…
CT.gov Mar 30, 2026